

19 JUN 2001

Docket No. 2861-4003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Sylvain CHEMTOB et al.

Group Art Unit: To Be Assigned

Serial No.: 09/787,334

Examiner: To Be Assigned

Filed: March 16, 2001

For: G PROTEIN-COUPLED RECEPTOR ANTAGONISTS

**TRANSMITTAL LETTER**

COMMISSIONER FOR PATENTS  
BOX PCT  
Washington, D.C. 20231

Sir:

Transmitted herewith is:

- 1) Express Mail Certificate, including Express Mail Label No. EL762621729US
- 2) Response to Notification of Missing Requirements under 35 USC 371 in the United States Designated/Elected Office (DO/EO/US), including copy of Notification of Missing Requirements under 35 USC 371 in the United States Designated/Elected Office (DO/EO/US)
- 3) Check for \$65.00
- 4) Executed Combined Declaration and Power of Attorney for Original, Design, National Stage of PCT, Supplemental Divisional, Continuation or Continuation-in-Part Application
- 5) Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 copies), including copy of Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- 6) Statement under 37 C.F.R. § 1.821(f), including substitute paper copy of sequence listing and diskette containing substitute computer readable sequence listing
- 7) Preliminary Amendment
- 8) Return receipt postcard

The Commissioner is hereby authorized to charge any additional fees which may be required by any of these papers, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2861-4003. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: June 19, 2001

By: 

Mary J. Morry  
Registration No. 34,398

Mailing Address:  
MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800

PROFESSOR 19 JUN 2001

2861-4003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Sylvain CHEMTOB et al. Group Art Unit: TBA  
Serial No : 09/787,334 Examiner: TBA  
Filed : March 16, 2001  
For : G PROTEIN-COUPLED RECEPTOR ANTAGONISTS

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER  
35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE  
(DO/EO/US)**

COMMISSIONER FOR PATENTS  
BOX PCT  
Washington, D.C. 20231


ATTENTION: Shakeel Ahmed

Dear Sir:

In response to the NOTIFICATION OF MISSING REQUIREMENTS UNDER 35  
U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)  
mailed April 23, 2001, submitted herewith is the executed Combined Declaration and Power  
of Attorney for Original, Design, National Stage of PCT, Supplemental Divisional,  
Continuation or Continuation-in-Part Application, signed by the named inventors, together  
with the Fee of \$65.00 for a small entity, as well as a copy of the Notification itself.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: June 19, 2001  
MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800 Telephone

By:   
Mary J. Morry  
Registration No. 34,398

Docket No. 2861-4003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Sylvain CHEMTOB et al.

Group Art Unit: To Be Assigned

Serial No.: 09/787,334

Examiner: To Be Assigned

Filed: March 16, 2001

For: G PROTEIN-COUPLED RECEPTOR ANTAGONISTS

**EXPRESS MAIL CERTIFICATE**Express Mail Label No.: **EL762621729US**Date of Deposit: **June 19, 2001**

I hereby certify that the following attached paper(s) and/or fee

- 1) Transmittal Letter (2 copies)
- 2) Response to Notification of Missing Requirements under 35 USC 371 in the United States Designated/Elected Office (DO/EO/US), including copy of Notification of Missing Requirements under 35 USC 371 in the United States Designated/Elected Office (DO/EO/US)
- 3) Check for \$65.00
- 4) Executed Combined Declaration and Power of Attorney for Original, Design, National Stage of PCT, Supplemental Divisional, Continuation or Continuation-in-Part Application
- 5) Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 copies), including copy of Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- 6) Statement under 37 C.F.R. § 1.821(f), including substitute paper copy of sequence listing and diskette containing substitute computer readable sequence listing
- 7) Preliminary Amendment
- 8) Return receipt postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PCT, Washington, D.C. 20231.


06/22/2001 ATRAM1 00000022 09787334

01 FC:254

65.00 OP

F. Garcia

(Typed or printed name of person mailing papers(s) and/or fee)

  
(Signature of person mailing paper(s) and/or fee)**Correspondence Address:**

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile

2861-4003  
Morry.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/787334	CHEMTOB	S 2861-4003
MORGAN & FINNEGAN 345 PARK AVENUE NEW YORK, NY 10154 0053		INTERNATIONAL APPLICATION NO. PCT/CA99/00844
I.A. FILING DATE		PRIORITY DATE
15 SEP 99		17 SEP 98

DATE MAILED: 23 APR 2001

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):
- ☒ U.S. Basic National Fee. ☒ Indication of Small Entity Status.
  - ☒ Copy of the international application. ☐ Translation of the international application into English.
  - ☐ Oath or Declaration of inventors(s). ☐ Translation of Article 19 amendments into English.
  - ☐ Copy of Article 19 amendments. ☐ Other:
  - ☒ Priority Document.
  - ☒ The International Preliminary Examination Report in English and its Annexes, if any.
  - ☐ Translation of Annexes to the International Preliminary Examination Report into English.
2. ☒ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- ☐ U.S. Basic National Fee. ☐ Copy of the international application.
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
  - ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
  - ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
  - ☒ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
  - ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
  - ☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$ \_\_\_\_\_ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

**ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(u).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

**A copy of this notice MUST be returned with this response.**

Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation  
☐ PTO-875 ☒ PCT/DO/EO/920

Shakeel Ahmed

FORM PCT/DO/EO/905 (March 2001)

Telephone: 703-305-3659

CASE 2861-4003

FILE DATE 2001-04-23

STATUTORY DATE 2001-04-23

BY J.M.